While Big Pharma frets over the costs and risks associated with exploratory endpoints in the clinic and the vagaries of companion diagnostic reimbursement, non-profit organizations like the Multiple Myeloma Research Foundation (MMRF) are stepping in to provide pharmacogenomic research for the next generation of cancer drugs.
PharmExec Blog
Follow Us
RSS
Bookstore
Bringing Genetic Data into the Clinic